Spondyloarthritis & psoriatic arthritis
Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis
Authors' conclusion
Concomitant use of MTX and biologics did not improve ACR efficacy outcomes versus biologic monotherapy.
Study context
- Population
- Adults with active PsA17 studies
- Comparison
- Biologics with vs without methotrexate (MTX)
- Outcome
- ACR20, ACR50 and ACR70 improvement response
Methodological detailsBayesian network meta-analysis (NMA), randomised, double-blinded, controlled trials
- Bayesian NMA
- Randomised, double-blinded, controlled trials
Pooled result
As reported in the abstract
ACR20/50
- No statistically significant differences between biologic monotherapy (all classes) and biologics with MTX for ACR20/50
- ACR20: all active treatments significantly better than placebo
Further pooled results
Comparison between biologic classes
- ACR20: IL-17i comparable to IL-23i
- ACR20: IL-17i significantly better than tumour necrosis factor inhibitors (TNFi)
- ACR50/70: TNFi, IL-23i and IL-17i not statistically different
- Limited by fewer trials (ACR50/70)
Original publication
Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD Open. Published 31 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →